TLR9 Inhibitors
Toll-like Receptor 9 (TLR9) inhibitors constitute a specialized category of chemical compounds meticulously engineered to selectively target and modulate the activity of TLR9, a pivotal component of the innate immune system. Toll-like receptors are integral to immune surveillance, as they recognize pathogen-associated molecular patterns, serving as sentinels against microbial invaders. TLR9 specifically discerns unmethylated CpG motifs prevalent in bacterial and viral DNA, initiating robust immune responses to combat threats. The design and development of TLR9 inhibitors focus on strategically interacting with discrete binding sites on the TLR9 receptor, disrupting its typical activation cascade. The intricate chemical structures of TLR9 inhibitors encompass a spectrum of functional groups, carefully tailored to optimize binding affinity and selectivity for the TLR9 receptor. Through this targeted interference, these inhibitors effectively modulate TLR9-mediated immune responses. The rationale behind this modulation lies in the utility of TLR9 inhibitors in regulating immune reactions, offering a means to attenuate excessive inflammation or mitigate autoimmunity. The diverse chemical landscape of TLR9 inhibitors reflects ongoing efforts to enhance their efficacy and specificity, contributing to the expanding toolbox for immune-related research.
The advancement of TLR9 inhibitors not only sheds light on the intricacies of immune regulation at the molecular level but also holds promise for the development of innovative strategies in immune-related research. By dissecting the molecular interactions between TLR9 and its inhibitors, researchers can glean insights into the nuanced mechanisms governing immune responses, fostering a deeper understanding of the immune system's complexities. The evolution of TLR9 inhibitors stands as a testament to the interdisciplinary efforts at the interface of chemistry and immunology, providing researchers with valuable tools to explore the intricate tapestry of innate immunity and paving the way for future breakthroughs in immune modulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, traditionally an antimalarial drug, acts as an indirect inhibitor of TLR9. It raises endosomal pH, inhibiting TLR9's proper localization and function. By preventing TLR9 from recognizing CpG motifs within endosomes, chloroquine hinders the initiation of TLR9-mediated signaling and subsequent immune responses. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Resiquimod (R848) is a small molecule that indirectly influences TLR9 activity by targeting TLR7. It activates TLR7 and induces the production of type I interferons, which can suppress TLR9 signaling. This crosstalk between TLR7 and TLR9 pathways results in the modulation of the overall TLR9-mediated immune response. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 is an inhibitor of NF-κB activation, indirectly impacting TLR9 signaling. It suppresses the phosphorylation and degradation of IκBα, preventing NF-κB translocation to the nucleus. By disrupting the NF-κB pathway, Bay 11-7082 attenuates the expression of pro-inflammatory genes downstream of TLR9 activation. | ||||||
Quinacrine, Dihydrochloride | 69-05-6 | sc-204222 sc-204222B sc-204222A sc-204222C sc-204222D | 100 mg 1 g 5 g 200 g 300 g | $46.00 $57.00 $87.00 $3257.00 $4821.00 | 4 | |
Quinacrine is an antimalarial drug with indirect inhibitory effects on TLR9. It interferes with endosomal acidification, disrupting TLR9 localization. By altering the endosomal environment, quinacrine impairs the proper recognition of CpG motifs by TLR9, leading to the inhibition of downstream TLR9-mediated signaling pathways. | ||||||
BAY 11-7085 | 196309-76-9 | sc-202490 sc-202490A | 10 mg 50 mg | $124.00 $526.00 | 55 | |
BAY 11-7085 is a pharmacological inhibitor that indirectly modulates TLR9 signaling by targeting the NF-κB pathway. It inhibits IκBα phosphorylation and degradation, hindering the nuclear translocation of NF-κB. This disruption in the NF-κB pathway leads to the downregulation of pro-inflammatory genes downstream of TLR9 activation. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
Janus Kinase Inhibitor I is a small molecule inhibitor that indirectly influences TLR9 signaling by targeting the JAK-STAT pathway. It inhibits Janus kinases (JAKs), disrupting downstream signaling events. By interfering with the JAK-STAT pathway, this inhibitor modulates the expression of genes involved in the TLR9-mediated immune response. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a small molecule inhibitor that indirectly modulates TLR9 signaling by targeting the p38 MAPK pathway. It inhibits p38 MAPK, influencing downstream signaling events. By disrupting the p38 MAPK pathway, SB203580 attenuates the expression of pro-inflammatory genes downstream of TLR9 activation, leading to an overall modulation of the immune response. | ||||||